Latest gene expression Stories

UCSF cell biologists find molecule targets a key biological pathway Memory improved in mice injected with a small, drug-like molecule discovered by UCSF San Francisco researchers studying how cells respond to biological stress. The same biochemical pathway the molecule acts on might one day be targeted in humans to improve memory, according to the senior author of the study, Peter Walter, PhD, UCSF professor of biochemistry and biophysics and a Howard Hughes Investigator. The...

Because of their central importance to biology, proteins have been the focus of intense research, particularly the manner in which they are produced from genetically coded templates—a process commonly known as translation. While the general mechanism of translation has been understood for some time, protein synthesis can initiate by more than one mechanism. One of the least well understood mechanisms is known as cap-independent translation. Now, John Chaput and his colleagues at Arizona...

A study led by St. Jude Children's Research Hospital shows epigenetic changes that turn genes on and off are as unique as alterations in DNA and may be as important in causing the most common childhood cancer MEMPHIS, Tenn., June 10, 2013 /PRNewswire-USNewswire/ -- Changes in an epigenetic mechanism that turns expression of genes on and off may be as important as genetic alterations in causing pediatric acute lymphoblastic leukemia (ALL), according to a study led by scientists...

Structural and molecular differences between human Argonaute proteins reveal essential elements for RNA-slicing Human Argonautes (hAgo), are key proteins involved in a process known as RNA interference. RNAi, as it is often called, is a mechanism that cells use to regulate gene expression. Human Argonaute-2 (hAgo2) is known as "slicer" for its unique ability among the 4 human Argonaute proteins to directly cut messenger RNA -- which carries the information coded in genomic DNA to make a...

- Clontech's SMART(TM) Technology Combined with Rubicon's ThruPLEX(TM) Pre-Analytical Technology Enables Researchers to Conduct High Quality RNA Seq Studies from Very Low Amounts of Total RNA - MOUNTAIN VIEW, Calif. and ANN ARBOR, Mich., June 6, 2013 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and Rubicon Genomics, Inc. announced today that they have partnered to integrate Clontech's SMART technology with Rubicon's ThruPLEX technology...

Correlation of protein phenotype brings researchers one step closer to personalized cancer treatment MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center. The study results, which compared MET protein expression with protein/gene expression of EMT markers and evaluated impact on...

Test Validated by Largest Melanoma Biomarker Program of its Kind Data Being Presented at American Society of Clinical Oncology Annual Meeting FRIENDSWOOD, Texas, June 3, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #9022). Results show that the gene expression profile test strongly predicts...

Financing from High Net-Worth Private Investors to Fuel RNAi Delivery Technologies for the Treatment of Disease SAN DIEGO, June 3, 2013 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada. (Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO) Arcturus...

PALO ALTO, Calif., May 30, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the Jefferies 2013 Global Healthcare Conference, taking place June 3-6, 2013 in New York, NY. David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and Corus(®) CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD)...

How does the bacterium Shigella—the cause of a deadly diarrheal disease—detect that it's in a human host? Ohio University scientists have found that a biological "RNA thermometer" monitors whether the environment is right for the bacterium to produce the factors it needs to survive within the body, according to a study published May 21 in the journal PLOS ONE. The scientists have been seeking more information about the genetic pathways of Shigella in the hope of finding new treatment...